APX005M in Combination With Systemic Pembrolizumab in Patients With Metastatic Melanoma
- Status
- TERMINATED
- Phase
- PHASE1/PHASE2
Clinical Trials Related to Pembrolizumab
Related studies linked through entity extraction aliases.
Switch Maintenance Pembrolizumab in Patients With NSCLC After First Line Platinum Doublet Chemotherapy
- Status
- COMPLETED
- Phase
- PHASE2
Pembrolizumab and GM-CSF in Biliary Cancer
- Status
- COMPLETED
- Phase
- PHASE2
Study of Pembrolizumab (MK-3475) as Monotherapy in Participants With Advanced Hepatocellular Carcinoma (MK-3475-224/KEYNOTE-224)
- Status
- COMPLETED
- Phase
- PHASE2
Study of Pembrolizumab (MK-3475) vs. Best Supportive Care in Participants With Previously Systemically Treated Advanced Hepatocellular Carcinoma (MK-3475-240/KEYNOTE-240)
- Status
- COMPLETED
- Phase
- PHASE3
Efficacy Study of Pembrolizumab With Entinostat to Treat Metastatic Melanoma of the Eye
- Status
- COMPLETED
- Phase
- PHASE2
A Study of Pembrolizumab in Patients With Malignant Peripheral Nerve Sheath Tumor (MPNST), Not Eligible for Curative Surgery
- Status
- TERMINATED
- Phase
- PHASE2
Pembrolizumab With or Without Vismodegib in Treating Metastatic or Unresectable Basal Cell Skin Cancer
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
Combination Margetuximab and Pembrolizumab for Advanced, Metastatic HER2(+) Gastric or Gastroesophageal Junction Cancer
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
Pembrolizumab in Anaplastic/Undifferentiated Thyroid Cancer
- Status
- COMPLETED
- Phase
- PHASE2
Study of Pembrolizumab (MK-3475) in Combination With Dinaciclib (MK-7965) in Hematologic Malignancies (MK-3475-155/KEYNOTE-155)
- Status
- TERMINATED
- Phase
- PHASE1
Phase II Trial of Sequential Consolidation With Pembrolizumab Followed by Nab-paclitaxel
- Status
- COMPLETED
- Phase
- PHASE2
Study of Pembrolizumab (MK-3475) vs. Brentuximab Vedotin in Participants With Relapsed or Refractory Classical Hodgkin Lymphoma (MK-3475-204/KEYNOTE-204)
- Status
- COMPLETED
- Phase
- PHASE3
Clinical Study of CMP-001 in Combination With Pembrolizumab or as a Monotherapy
- Status
- COMPLETED
- Phase
- PHASE1
Sequential Intranodal Immunotherapy (SIIT) Combined With Anti-PD1 (Pembrolizumab) in Follicular Lymphoma
- Status
- COMPLETED
- Phase
- PHASE2
Phase 1 Study of IMP321 (Eftilagimod Alpha) Adjuvant to Anti-PD-1 Therapy in Unresectable or Metastatic Melanoma
- Status
- COMPLETED
- Phase
- PHASE1
CGX1321 in Subjects With Advanced Solid Tumors and CGX1321 With Pembrolizumab or Encorafenib + Cetuximab in Subjects With Advanced GI Tumors (Keynote 596)
- Status
- UNKNOWN
- Phase
- PHASE1
Efficacy and Safety Study of Pembrolizumab (MK-3475) in Participants With Advanced Recurrent Ovarian Cancer (MK-3475-100/KEYNOTE-100)
- Status
- COMPLETED
- Phase
- PHASE2
Single Agent Pembrolizumab in Subjects With Advanced Adrenocortical Carcinoma
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Study of the Combination of AFM13 and Pembrolizumab in Patients With Relapsed or Refractory Classical Hodgkin Lymphoma
- Status
- COMPLETED
- Phase
- PHASE1